Companies › Oscotec
2 active drug programs in 2 registered trials: 2 Phase 1; Immunology, Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SKI-O-703 API in Capsules | – | Phase 1 | Bioequivalence Study in Healthy Subjects | Dec 2026 |
| OCT-598 | – | Phase 1 | Solid Tumor | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07675226 | SKI-O-703 API in Capsules | Phase 1 | Bioequivalence Study in Healthy Subjects | Immunology | Dec 2026 |
| NCT07358806 | OCT-598 | Phase 1 | Solid Tumor | Oncology | Dec 2027 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.